Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients
Background: Highly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed. However, the emergence of viral variants that are more infectious than the earlier SARS-CoV-2 strains is concerning. Several of these viral variants have the potential to...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-11-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396421004199 |
| _version_ | 1819013435843674112 |
|---|---|
| author | Juan Manuel Carreño Hala Alshammary Gagandeep Singh Ariel Raskin Fatima Amanat Angela Amoako Ana Silvia Gonzalez-Reiche Adriana van de Guchte PARIS study group Komal Srivastava Emilia Mia Sordillo D. Noah Sather Harm van Bakel Florian Krammer Viviana Simon |
| author_facet | Juan Manuel Carreño Hala Alshammary Gagandeep Singh Ariel Raskin Fatima Amanat Angela Amoako Ana Silvia Gonzalez-Reiche Adriana van de Guchte PARIS study group Komal Srivastava Emilia Mia Sordillo D. Noah Sather Harm van Bakel Florian Krammer Viviana Simon |
| author_sort | Juan Manuel Carreño |
| collection | DOAJ |
| description | Background: Highly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed. However, the emergence of viral variants that are more infectious than the earlier SARS-CoV-2 strains is concerning. Several of these viral variants have the potential to partially escape neutralizing antibody responses, warranting continued immune-monitoring. Methods: We used a panel of 30 post-mRNA vaccination sera to determine neutralization and RBD and spike binding activity against a number of emerging viral variants. The virus neutralization was determined using authentic SARS-CoV-2 clinical isolates in an assay format that mimics physiological conditions. Findings: We tested seven currently circulating viral variants of concern/interest, including the three Iota sublineages, Alpha (E484K), Beta, Delta and Lambda in neutralization assays. We found only small decreases in neutralization against Iota and Delta. The reduction was stronger against a sub-variant of Lambda, followed by Beta and Alpha (E484K). Lambda is currently circulating in parts of Latin America and was detected in Germany, the US and Israel. Of note, reduction in a receptor binding domain and spike binding assay that also included Gamma, Kappa and A.23.1 was negligible. Interpretation: Taken together, these findings suggest that mRNA SARS-CoV-2 vaccines may remain effective against these viral variants of concern/interest and that spike binding antibody tests likely retain specificity in the face of evolving SARS-CoV-2 diversity. Funding: This work is part of the PARIS/SPARTA studies funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051. In addition, this work was also partially funded by the Centers of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C), the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384), by anonymous donors and by the Serological Sciences Network (SeroNet) in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003. |
| first_indexed | 2024-12-21T01:59:54Z |
| format | Article |
| id | doaj.art-fab401c41070495fad05e747924fb0a0 |
| institution | Directory Open Access Journal |
| issn | 2352-3964 |
| language | English |
| last_indexed | 2024-12-21T01:59:54Z |
| publishDate | 2021-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EBioMedicine |
| spelling | doaj.art-fab401c41070495fad05e747924fb0a02022-12-21T19:19:40ZengElsevierEBioMedicine2352-39642021-11-0173103626Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipientsJuan Manuel Carreño0Hala Alshammary1Gagandeep Singh2Ariel Raskin3Fatima Amanat4Angela Amoako5Ana Silvia Gonzalez-Reiche6Adriana van de Guchte7PARIS study group8Komal Srivastava9Emilia Mia Sordillo10D. Noah Sather11Harm van Bakel12Florian Krammer13Viviana Simon14Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USADepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USADepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USADepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USADepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USADepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USADepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USADepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USADepartment of Pathology, Molecular and Cell Based Medicine Icahn School of Medicine at Mount Sinai, New York, NY, USACenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, United States; Department of Pediatrics, University of Washington, Seattle, WA, USADepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Corresponding author at: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell Based Medicine Icahn School of Medicine at Mount Sinai, New York, NY, USA; Corresponding authors at: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell Based Medicine Icahn School of Medicine at Mount Sinai, New York, NY, USA; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Corresponding authors at: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.Background: Highly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed. However, the emergence of viral variants that are more infectious than the earlier SARS-CoV-2 strains is concerning. Several of these viral variants have the potential to partially escape neutralizing antibody responses, warranting continued immune-monitoring. Methods: We used a panel of 30 post-mRNA vaccination sera to determine neutralization and RBD and spike binding activity against a number of emerging viral variants. The virus neutralization was determined using authentic SARS-CoV-2 clinical isolates in an assay format that mimics physiological conditions. Findings: We tested seven currently circulating viral variants of concern/interest, including the three Iota sublineages, Alpha (E484K), Beta, Delta and Lambda in neutralization assays. We found only small decreases in neutralization against Iota and Delta. The reduction was stronger against a sub-variant of Lambda, followed by Beta and Alpha (E484K). Lambda is currently circulating in parts of Latin America and was detected in Germany, the US and Israel. Of note, reduction in a receptor binding domain and spike binding assay that also included Gamma, Kappa and A.23.1 was negligible. Interpretation: Taken together, these findings suggest that mRNA SARS-CoV-2 vaccines may remain effective against these viral variants of concern/interest and that spike binding antibody tests likely retain specificity in the face of evolving SARS-CoV-2 diversity. Funding: This work is part of the PARIS/SPARTA studies funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051. In addition, this work was also partially funded by the Centers of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C), the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384), by anonymous donors and by the Serological Sciences Network (SeroNet) in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003.http://www.sciencedirect.com/science/article/pii/S2352396421004199SARS-CoV-2 variantsCOVID-19COVID-19 mRNA vaccinesAntibodiesNeutralization activityVoC |
| spellingShingle | Juan Manuel Carreño Hala Alshammary Gagandeep Singh Ariel Raskin Fatima Amanat Angela Amoako Ana Silvia Gonzalez-Reiche Adriana van de Guchte PARIS study group Komal Srivastava Emilia Mia Sordillo D. Noah Sather Harm van Bakel Florian Krammer Viviana Simon Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients EBioMedicine SARS-CoV-2 variants COVID-19 COVID-19 mRNA vaccines Antibodies Neutralization activity VoC |
| title | Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients |
| title_full | Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients |
| title_fullStr | Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients |
| title_full_unstemmed | Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients |
| title_short | Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients |
| title_sort | evidence for retained spike binding and neutralizing activity against emerging sars cov 2 variants in serum of covid 19 mrna vaccine recipients |
| topic | SARS-CoV-2 variants COVID-19 COVID-19 mRNA vaccines Antibodies Neutralization activity VoC |
| url | http://www.sciencedirect.com/science/article/pii/S2352396421004199 |
| work_keys_str_mv | AT juanmanuelcarreno evidenceforretainedspikebindingandneutralizingactivityagainstemergingsarscov2variantsinserumofcovid19mrnavaccinerecipients AT halaalshammary evidenceforretainedspikebindingandneutralizingactivityagainstemergingsarscov2variantsinserumofcovid19mrnavaccinerecipients AT gagandeepsingh evidenceforretainedspikebindingandneutralizingactivityagainstemergingsarscov2variantsinserumofcovid19mrnavaccinerecipients AT arielraskin evidenceforretainedspikebindingandneutralizingactivityagainstemergingsarscov2variantsinserumofcovid19mrnavaccinerecipients AT fatimaamanat evidenceforretainedspikebindingandneutralizingactivityagainstemergingsarscov2variantsinserumofcovid19mrnavaccinerecipients AT angelaamoako evidenceforretainedspikebindingandneutralizingactivityagainstemergingsarscov2variantsinserumofcovid19mrnavaccinerecipients AT anasilviagonzalezreiche evidenceforretainedspikebindingandneutralizingactivityagainstemergingsarscov2variantsinserumofcovid19mrnavaccinerecipients AT adrianavandeguchte evidenceforretainedspikebindingandneutralizingactivityagainstemergingsarscov2variantsinserumofcovid19mrnavaccinerecipients AT parisstudygroup evidenceforretainedspikebindingandneutralizingactivityagainstemergingsarscov2variantsinserumofcovid19mrnavaccinerecipients AT komalsrivastava evidenceforretainedspikebindingandneutralizingactivityagainstemergingsarscov2variantsinserumofcovid19mrnavaccinerecipients AT emiliamiasordillo evidenceforretainedspikebindingandneutralizingactivityagainstemergingsarscov2variantsinserumofcovid19mrnavaccinerecipients AT dnoahsather evidenceforretainedspikebindingandneutralizingactivityagainstemergingsarscov2variantsinserumofcovid19mrnavaccinerecipients AT harmvanbakel evidenceforretainedspikebindingandneutralizingactivityagainstemergingsarscov2variantsinserumofcovid19mrnavaccinerecipients AT floriankrammer evidenceforretainedspikebindingandneutralizingactivityagainstemergingsarscov2variantsinserumofcovid19mrnavaccinerecipients AT vivianasimon evidenceforretainedspikebindingandneutralizingactivityagainstemergingsarscov2variantsinserumofcovid19mrnavaccinerecipients |